Observational studyBMC cardiovascular disorders2025
Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Inertia in Lipid-Lowering Treatment: A Narrative Review.Journal of clinical medicine · 2026Review
- The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts' Proposal.European cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic inertia is defined as the failure to provide guideline-directed therapy and is a barrier to achieving optimal clinical outcomes. We aimed to evaluate therapeutic inertia in statin therapy after percutaneous coronary intervention (PCI) and its association with patient characteristics and physician’s prescribing practice.
methodsWe analyzed the medical claims data on patients undergoing PCI using National Health Insurance Service in Republic of Korea. The primary outcome of interest was therapeutic inertia, defined as not providing high-intensity statin (HIS) therapy within 30 days after discharge for PCI. To identify statin use in identical clinical setting, we restricted study duration to between 2013 American College of Cardiology/American Heart Association cholesterol guideline and publications of RACING (Randomized Comparison of Efficacy and Safety of Lipid-lowering with Statin Monotherapy Versus Statin–ezetimibe Combination for High-risk Cardiovascular Disease) and LODESTAR (Low-Density Lipoprotein Cholesterol-Targeting Statin Therapy Versus Intensity-Based Statin Therapy in Patients With Coronary Artery Disease) trials that demonstrated non-inferiority of alternative statin strategies compared with HIS therapy in atherosclerotic cardiovascular disease. We also assessed patient characteristics affecting HIS prescription, statin switching before and after PCI among previous statin users, and impact of previous statin regimen on prescribing of HIS.
resultsOf 204,708 participants (mean age 66.5 ± 11.3 years, 30.8% female, 56.6% previous statin users, 43.4% previous statin nonusers), therapeutic inertia was identified in 64.1%, and HIS prescription rate was higher in previous statin nonusers (42.0%) than in previous statin users (31.1%). There were few differences in patient characteristics as positive (male and acute coronary syndrome as indication for PCI) and negative (increase of age, comorbidities, and cardiovascular medications) predictors of HIS prescription between previous statin users and nonusers. Because 79.1% of previous HIS users and 23.8% of previous non-HIS users received HIS following PCI, previous HIS users were more likely to be prescribed HIS as compared to previous statin nonusers (odds ratio, 5.42; 95% confidence intervals, 4.44–6.61) and previous non-HIS users (odds ratio, 12.30; 95% confidence intervals, 9.95–15.19).
conclusionsSuboptimal HIS prescription following PCI was substantially affected by patient characteristics and the practice of repetitive prescribing of previous statin without guideline-directed titration. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.